Oral remibrutinib hits Phase 3 primary endpoint for inducible hives
1. Oral remibrutinib successfully met its primary endpoint in the Phase III RemIND trial, delivering significant symptom relief for chronic...
1. Oral remibrutinib successfully met its primary endpoint in the Phase III RemIND trial, delivering significant symptom relief for chronic...
1. In this cohort of patients with Obstructive sleep apnea (OSA), a higher sleep apnea-specific hypoxic burden (SASHB) was associated...
1. Merck and Mayo Clinic have launched a strategic collaboration to integrate multimodal clinical data with AI to accelerate drug...
1. In this prospective cohort study, lifestyle behaviours, especially higher body mass index (BMI) and smoking, are associated with measurable...
1. Wang and colleagues developed a system that uses deep learning algorithms to analyze cover tests recorded by suspected strabismus...
1. In this phase 1-2 single-group trial, the p53 reactivator rezatapopt was well-tolerated in adults with solid tumors harboring the...
1. In this phase 1–2 open-label study, autologous lentiviral hematopoietic stem-cell gene therapy for cystinosis was associated with sustained engraftment...
1. In this prospective cohort, individuals with greater periods of sedentary time have increased risks of all-cause mortality and mortality...
1. In this randomized controlled trial, neither metformin nor ursodeoxycholic acid improved recovery from long COVID compared with placebo in...
1. For women at higher-than-average risk, adding supplemental MRI to DBT provided only modest additional benefit, resulting in a similar...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.